Status:
COMPLETED
Effects of Cilostazol on VEGF and Oxidative Stress Biomarkers in Hemodialysis Patients With Peripheral Vascular Disease
Lead Sponsor:
Tungs' Taichung Metroharbour Hospital
Conditions:
Hemodialysis Patients
Peripheral Vascular Disease
Eligibility:
All Genders
30-70 years
Phase:
PHASE4
Brief Summary
Peripheral arterial disease (PAD) is the most common manifestation of systemic atherosclerosis and accounts for significant morbidity and mortality among end-stage renal disease (ESRD) patients. Howev...
Detailed Description
Purpose : Patients with end stage renal disease are at an increased risk for cardiovascular disease (CVD) and the annual mortality from CVD in end-stage renal disease (ESRD) patients is substantially...
Eligibility Criteria
Inclusion
- Both sexes aged between 30-70 years
- Non-diabetic ESRD Patients on HD greater than 3 months
- Patients with PAD diagnosed by clinical symptoms, and ABI indices \< 0.9 and confirmed by angiographic or related studies.
- Written informed consent
Exclusion
- Known allergy to cilostazol
- Patients who currently have had pentoxyphylline or related therapy
- Congestive heart failure or cardiac arrhythmia
- Severe liver impairment
- Patients with malignancy or acute/chronic inflammatory diseases
- Smoking during the previous 6 months
- Recent stroke
- Severe dyslipidemia (triglycerides \>600 mg/dL or total cholesterol \>300g/dL) or currently on statin therapy
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00431249
Start Date
February 1 2007
End Date
April 1 2008
Last Update
May 12 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.